Document is current
Any future updates will be listed below
-
Authors
Kusui, Yuka
Izuo, Naotaka
Uno, Kyosuke
Ge, Bin
Muramatsu, Shin-ichi
Nitta, Atsumi https://orcid.org/0000-0001-6916-9160
-
Funding
Funding for this research was provided by:
Japan Society for the Promotion of Science (26293213, JP21H02632, AdAMS (Ac210045))
Kobayashi Foundation
Smoking Research Foundation
Japan Science and Technology Agency (JPMJSP2145)
- License Information
-
More Information
Article History
Received: 12 March 2022
Revised: 30 June 2022
Accepted: 6 July 2022
First Online: 29 July 2022
Declarations
:
: SM has equity in the Gene Therapy Research Institution, Co., Ltd., which commercializes the use of AAV vectors for gene therapy applications. To the extent that the work in this manuscript increases the value of these commercial holdings, SM has conflicts of interest. The other authors have no relevant financial or non-financial interests to disclose.
: All animal experiments followed the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals. Animal experimental protocols were approved by the Animal Care and Use Committee of the University of Toyama (Approval number: A2018PHA-13) and conducted in accordance with Institutional Animal Experiment Handling Rules of the University of Toyama. All procedures related to genetic modification followed the Guideline for Recombinant DNA Experiments from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and were approved by the Gene Recombination Experiment Safety Committee of the University of Toyama (Approval number: G2015PHA-14).
